A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Caribou Biosciences, Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 3,268 shares of CRBU stock, worth $9,085. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,268
Previous 2,696 21.22%
Holding current value
$9,085
Previous $4,000 50.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 23, 2024

BUY
$1.56 - $2.73 $892 - $1,561
572 Added 21.22%
3,268 $6,000
Q2 2024

Jul 30, 2024

SELL
$1.62 - $5.05 $368,543 - $1.15 Million
-227,496 Reduced 98.83%
2,696 $4,000
Q1 2024

May 01, 2024

BUY
$4.82 - $8.26 $272,744 - $467,400
56,586 Added 32.59%
230,192 $1.18 Million
Q4 2023

Jan 24, 2024

SELL
$3.58 - $6.25 $423,460 - $739,281
-118,285 Reduced 40.52%
173,606 $994,000
Q3 2023

Oct 26, 2023

BUY
$4.08 - $8.14 $164,105 - $327,407
40,222 Added 15.98%
291,891 $1.4 Million
Q2 2023

Aug 10, 2023

BUY
$4.04 - $5.47 $114,865 - $155,523
28,432 Added 12.74%
251,669 $1.07 Million
Q1 2023

May 04, 2023

BUY
$4.3 - $7.78 $45,519 - $82,359
10,586 Added 4.98%
223,237 $1.19 Million
Q4 2022

Feb 09, 2023

SELL
$5.57 - $11.01 $217,113 - $429,158
-38,979 Reduced 15.49%
212,651 $1.34 Million
Q3 2022

Nov 10, 2022

BUY
$5.34 - $12.79 $176,033 - $421,622
32,965 Added 15.08%
251,630 $2.66 Million
Q2 2022

Jul 26, 2022

BUY
$5.1 - $9.74 $344,250 - $657,450
67,500 Added 44.65%
218,665 $1.19 Million
Q1 2022

Jun 02, 2022

BUY
$8.42 - $15.32 $1.27 Million - $2.32 Million
151,165 New
151,165 $1.39 Million
Q1 2022

May 10, 2022

SELL
$8.42 - $15.32 $1.51 Million - $2.74 Million
-178,913 Closed
0 $0
Q4 2021

Feb 08, 2022

BUY
$14.59 - $23.26 $2.61 Million - $4.16 Million
178,913 New
178,913 $2.7 Million

Others Institutions Holding CRBU

About Caribou Biosciences, Inc.


  • Ticker CRBU
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,840,800
  • Market Cap $169M
  • Description
  • Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...
More about CRBU
Track This Portfolio

Track Mirae Asset Global Investments Co., Ltd. Portfolio

Follow Mirae Asset Global Investments Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.